Vijayakumar, Dhanya
Jankovic, Joseph http://orcid.org/0000-0001-5551-3784
Article History
Accepted: 23 January 2022
First Online: 25 February 2022
Declarations
:
: No funding was received.
: Dhanya Vijayakumar, MD declares no conflict of interest. Joseph Jankovic, MD has received grants from AbbVie Inc; Acadia Pharmaceuticals; Cerevel Therapeutics; CHDI Foundation; Dystonia Coalition; Emalex Biosciences, Inc; F. Hoffmann-La Roche Ltd; Huntington Study Group; Medtronic Neuromodulation; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; National Institutes of Health; Neuraly, Inc.; Neurocrine Biosciences; Parkinson’s Foundation; Parkinson Study Group; Prilenia Therapeutics; Revance Therapeutics, Inc; and Teva Pharmaceutical Industries Ltd. He also receives consulting fees from Aeon BioPharma; Allergan, Inc; Merck & Co, Inc; Revance Therapeutics; Teva Pharmaceutical Industries Ltd. and receives royalties from Cambridge; Elsevier; Medlink: Neurology; Lippincott Williams and Wilkins; UpToDate; Wiley-Blackwell. The authors have no other relevant affiliations or financial conflict of interest with the subject discussed in the manuscript apart from those disclosed.
: No ethical approval required.
: Not applicable.
: Not applicable.
: Data was obtained from previously published articles.
: Not applicable.
: All authors made substantial contributions to drafting and revising the manuscript for intellectual content. The first draft of the manuscript was written by Dhanya Vijayakumar, MD and Joseph Jankovic, MD revised and commented on previous versions of the manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.